Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported third quarter 2025 results and announced a major expansion of its pipeline with a new induced pluripotent stem cell (iPSC)-derived beta …
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 Read More